US Diabetes Care Drugs Market Analysis
The US Diabetes Care Drugs Market size is estimated at USD 33.80 billion in 2025, and is expected to reach USD 40.53 billion by 2030, at a CAGR of 3.7% during the forecast period (2025-2030).
The prevalence of diabetes in the United States is rapidly increasing, as indicated by the latest data from the CDC's National Diabetes Statistics Report for 2022. The report estimates that there are now approximately 37.3 million cases of diabetes in the country. This accounts for 11.3% of the U.S. population.
Out of these cases, around 28.7 million individuals have already been diagnosed with diabetes, while approximately 8.6 million people remain undiagnosed. It is important to note that diabetes affects individuals from all social, economic, and ethnic backgrounds. Furthermore, nearly half of the population aged 65 years or older, which amounts to 26.4 million people, have prediabetes.
According to the World Health Organization (WHO), the risk of diabetes has increased in North America due to the aging population. With advancements in healthcare, people are living longer, resulting in a significant percentage of the aging population being diagnosed with diabetes. The rising number of diabetes cases includes individuals who have recently developed the condition, particularly young individuals with unhealthy lifestyles. Additionally, there is an increase in the number of older adults who have been diagnosed with diabetes due to the availability of newer tests and increased screening.
Based on drugs, the insulin segment holds a significant share in the market. Over 100 million people around the world need insulin, including all the people suffering from Type-1 diabetes and between 10% and 25% of people with Type-2 diabetes. Production of insulin is very complex, and there are very few companies in the market that manufacture insulin. Due to this, there is high competition between these manufacturers, who always strive to meet the patient's needs to supply the best-quality insulin.
US Diabetes Care Drugs Market Trends
Oral-Anti Diabetes Drugs Segment is Having the Highest Market Share in Current Year
The Oral-Anti Diabetes Drugs segment is expected to increase with a CAGR of over 5.4 % during the forecast period, mainly due to the demand from the diabetes population, which was more than 26 million by the end of the forecast period.
According to the International Diabetes Federation, Type 1 diabetes patients spend most of their money on insulin medicines. Only a small percentage of Type 2 diabetes patients require insulin. Although Type 1 diabetes affects just 10% of the population, their insulin consumption is greater. Increased knowledge of the advantages of insulin for diabetes patients, particularly in emerging nations, is driving the demand for insulin. Other reasons, such as quick advancement in insulin delivery methods, medication and analog research by major pharmaceutical firms, and an increase in the elderly and obese population, may fuel the insulin market's growth.
In the Oral Anti Diabetes Drugs segment, Metformin has the highest share. Metformin is a biguanide medication used to treat type 2 diabetes. It is given for "off-label" usage in patients suffering from diseases such as insulin resistance. Since introducing Metformin into T2DM therapy, many patients have been effectively treated with this internationally available medicine with a favorable risk/benefit profile recommended as a first-line prescription by IDF guidelines.
As a result, Metformin remains the most prescribed oral antidiabetic drug globally, accounting for 45-50% of all prescriptions and being used by over 150 million individuals each year. Long-term favorable experience with metformin usage, solid evidence of clinical efficacy and safety, high adherence rate, cheap cost, broad availability, and cost-effectiveness all contribute to the large market share.
Thus, the above factors are expected to drive the market growth over the forecast period.
Increasing Diabetes Population in the United States
The United States dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and the launch of new drugs. The United States is expected to grow tremendously during the forecast period, owing to factors such as the high prevalence of obesity and increasing awareness regarding diabetes care. North America remained the largest market for insulin drugs, primarily due to high demand from the United States. Diabetic drugs are medicines developed to stabilize and control blood glucose levels among people with diabetes.
In July 2022, Zydus Lifesciences announced that it had received final approval from the USFDA to market Empagliflozin and Metformin Hydrochloride tablets in multiple strengths. Empagliflozin and Metformin Hydrochloride tablets are used with proper diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. They are also used to lower the risk of cardiovascular death in patients with type 2 diabetes mellitus and established cardiovascular disease.
Thus, the above factors are expected to drive the market growth over the forecast period.
US Diabetes Care Drugs Industry Overview
Manufacturers have constantly innovated to compete and battle in the industry under study. According to a new study on the SGLT2 Class (Jardiance, Farxiga), medicine aids in treating renal and cardiovascular illnesses.
US Diabetes Care Drugs Market Leaders
Eli Lilly
Boehringer Ingelheim
Astrazeneca
Sanofi
NovoNordisk
- *Disclaimer: Major Players sorted in no particular order
US Diabetes Care Drugs Market News
- June 2023: The initial allogeneic pancreatic islet cellular therapy, Lantidra, has been sanctioned by the U.S. Food and Drug Administration. This treatment, derived from deceased donor pancreatic cells, is specifically designed for individuals with type 1 diabetes. Lantidra is intended for adults who struggle to achieve target glycated hemoglobin levels due to frequent severe hypoglycemia episodes, despite undergoing intensive diabetes management and education.
- June 2023: The U.S. Food and Drug Administration has authorized the use of Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) in combination with diet and exercise to enhance blood sugar control in children aged 10 and older with type 2 diabetes. This approval marks the introduction of a new class of oral medications for managing pediatric type 2 diabetes.
